Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
APLS Apellis Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: APLS
Price (delayed)
$20.03
Market cap
$2.52B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.79
Enterprise value
$2.63B
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, the company aims
Highlights
APLS's revenue is up by 48% year-on-year
The EPS is up by 48% year-on-year but it has declined by 12% since the previous quarter
APLS's net income is up by 46% year-on-year but it is down by 13% since the previous quarter
The equity has declined by 38% year-on-year and by 28% since the previous quarter
The company's gross margin fell by 4% YoY and by 2.2% QoQ
Key stats
What are the main financial stats of APLS
Market
Valuations
Earnings
Shares outstanding
125.68M
Market cap
$2.52B
Enterprise value
$2.63B
Price to earnings (P/E)
N/A
Price to book (P/B)
15.31
Price to sales (P/S)
3.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.39
Revenue
$775.84M
Gross profit
$643.97M
Operating income
-$186.22M
Net income
-$223.68M
EBIT
-$177.87M
EBITDA
-$176.07M
Free cash flow
-$8.41M
Per share
Balance sheet
Liquidity
EPS
-$1.79
EPS diluted
-$1.79
Free cash flow per share
-$0.07
Book value per share
$1.31
Revenue per share
$6.18
TBVPS
$6.43
Total assets
$807.29M
Total liabilities
$643.07M
Debt
$469.55M
Equity
$164.22M
Working capital
$549.34M
Debt to equity
2.86
Current ratio
4.08
Quick ratio
3.34
Net debt/EBITDA
-0.62
Margins
Efficiency
Dividend
EBITDA margin
-22.7%
Gross margin
83%
Net margin
-28.8%
Operating margin
-24%
Return on assets
-25.6%
Return on equity
-100.1%
Return on invested capital
-22.8%
Return on capital employed
-28.3%
Return on sales
-22.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
APLS stock price
How has the Apellis Pharmaceuticals stock price performed over time
Intraday
3.03%
1 week
14.98%
1 month
6.37%
1 year
-49.33%
YTD
-37.23%
QTD
15.71%
Financial performance
How have Apellis Pharmaceuticals's revenue and profit performed over time
Revenue
$775.84M
Gross profit
$643.97M
Operating income
-$186.22M
Net income
-$223.68M
Gross margin
83%
Net margin
-28.8%
APLS's operating margin has surged by 69% year-on-year but it is down by 14% since the previous quarter
The company's net margin has surged by 64% YoY but it fell by 14% QoQ
APLS's operating income has surged by 54% year-on-year but it is down by 13% since the previous quarter
APLS's revenue is up by 48% year-on-year
Price vs fundamentals
How does APLS's price correlate with its fundamentals
Growth
What is Apellis Pharmaceuticals's growth rate over time
Valuation
What is Apellis Pharmaceuticals stock price valuation
P/E
N/A
P/B
15.31
P/S
3.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.39
The EPS is up by 48% year-on-year but it has declined by 12% since the previous quarter
The P/B is 39% less than the 5-year quarterly average of 24.2 and 10% less than the last 4 quarters average of 16.6
The equity has declined by 38% year-on-year and by 28% since the previous quarter
The stock's price to sales (P/S) is 99% less than its 5-year quarterly average of 216.0 and 41% less than its last 4 quarters average of 5.3
APLS's revenue is up by 48% year-on-year
Efficiency
How efficient is Apellis Pharmaceuticals business performance
The company's return on invested capital has surged by 82% YoY
The return on sales has surged by 69% year-on-year but it has declined by 15% since the previous quarter
APLS's ROA is up by 49% year-on-year but it is down by 14% since the previous quarter
APLS's ROE is up by 38% YoY but it is down by 26% QoQ
Dividends
What is APLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for APLS.
Financial health
How did Apellis Pharmaceuticals financials performed over time
Apellis Pharmaceuticals's total assets is 26% more than its total liabilities
The company's quick ratio rose by 21% YoY but it fell by 8% QoQ
APLS's total liabilities is up by 14% year-on-year but it is down by 2% since the previous quarter
The company's debt is 186% higher than its equity
The debt to equity has increased by 39% since the previous quarter
The equity has declined by 38% year-on-year and by 28% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.